Source: Annual Congress 2012 - CPAP: beneficial effects on different aspects of health
Disease area: Sleep and breathing disorders



Rating:

Share or cite this content

Citations should be made in the following way:
J.K. Varga, G. Horvath, Z.I. Komlosi, G. Boszormenyi-Nagy, K. Vardi Visy, G. Losonczy, L. Kunos (Budapest, Hungary). CPAP therapy in OSA patients: The effects on healthcare use and medical costs related to cardio- and cerebrovascular diseases. Eur Respir J 2012; 40: Suppl. 56, 433

Member's Comments

No comment yet.

Related content which might interest you: Do cardiovascular drugs reduce mortality in patients with COPD in daily practice? A study in primary care Source: Annual Congress 2007 - Management of COPD: pushing forward the boundaries in primary care Year: 2007 Do cardiovascular drugs reduce exacerbations rates in primary care patients with COPD? Source: Eur Respir J 2007; 30: Suppl. 51, 126s Year: 2007 Management of patients with asthma or COPD and cardiovascular disease: risks versus benefits Source: Eur Respir Monogr 2020; 88: 66-81 Year: 2020 CPAP and measures of cardiovascular risks in patients with OSAS Source: Eur Respir J 2009; 33: 1520 Year: 2009 Optimising pharmacotherapy in patients with pulmonary arterial hypertension and comorbidities, including lung diseases and heart failure: benefits without harm? Source: International Congress 2018 – Integrated care for patients with pulmonary vascular disease, lung diseases and heart failure Year: 2018 Co-morbidities and cardiovascular medications are the best predictors of mortality in patients with obesity-associated hypoventilation treated with long-term non-invasive ventilation Source: Annual Congress 2012 - Current trends in home mechanical ventilation Year: 2012 Impacting patient-centred outcomes in COPD: exacerbations and hospitalisations Source: Eur Respir Rev 2006; 15: 47-51 Year: 2006 COPD - comorbidities and their impact on the need of medical care Source: International Congress 2019 – Long-term evaluation and control of airway diseases Year: 2019 Combination asthma medication and healthcare use in severe or difficult-to-treat asthma Source: Eur Respir J 2004; 24: Suppl. 48, 131s Year: 2004 Quantify comorbidities burden of chronic obstructive pulmonary disease patients using medication regimen complexity index Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 The impact of comorbidities on the short-term serious health outcomes in hospitalized COPD patients due to exacerbation Source: Annual Congress 2013 –COPD treatment and others Year: 2013 Impact of obstructive sleep apnea and CPAP treatment on mortality and cardio and cerebrovascular consequences in men of the general population after 20 years of follow-up. Source: Virtual Congress 2020 – From pathophysiology to clinical consequences of sleep and breathing disorders Year: 2020 Reasons of non-adherence to telemonitoring programs in patients with chronic respiratory diseases. Source: International Congress 2019 – Novel interventions and models of pulmonary rehabilitation Year: 2019 Can correct inhalation technique programs reduce costs due to hospitalization of patients with obstructive pulmonary diseases? Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients? Year: 2017 Educating cardiologists on COPD management to improve CVD outcomes Source: International Congress 2015 – Pulmonary hypertension in lung disease Year: 2015 The healthcare burden of non-compliance to pharmacotherapeutic escalation recommendations for COPD Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Effects of an eHealth intervention promoting correct use of medication in patients with asthma and chronic obstructive pulmonary disease Source: Virtual Congress 2021 – Remote monitoring of respiratory patients Year: 2021 The impact of paramedics‘ education on controlled oxygen prescribing for patients with acute exacerbations of COPD during ambulance transfers on outcomes Source: Annual Congress 2012 - Multidisciplinary critical care Year: 2012 QVA149 does not increase the risk of cardio- and cerebro-vascular events, pneumonia and exacerbation events compared with placebo: A network meta-analysis across multiple safety databases Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013